DNALite™ is a blood-based non-invasive test, which can be used by physicians for the detection of circulating DNA from pathological tissues.
The potential to use circulating tumour DNA (ctDNA) from blood as a surrogate tissue in diverse cancer types is coming of age and gaining momentum in the management of cancer. The ratio of ctDNA and normal circulating DNA (ncDNA) can be used both as diagnostics or to monitor treatment response. One of the encouraging results of a study by Bettegowda et al 2014., is that ctDNA was found in most of the patients with localized disease, when their chances of a favorable outcome are highest. It was shown that 47% patients with stage I disease, who are nearly always curable by surgery alone, have detectable levels of ctDNA in their plasma.
DNALite™ delivers results in just 2 to 3 days. Additional tests, like Mload™ and SourceLite™ can be conducted to define the pathology and primary source of cancer respectively.
Bettegowda et al., 2014, Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med. 6(224): 224ra24. doi:10.1126/scitranslmed.3007094.